- Home
- ZLAB vs TWST Comparison
ZLAB vs TWST Comparison
Compare ZLAB & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | TWST |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 3.0B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | TWST |
|---|---|---|
| Price | $20.54 | $51.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $49.60 | $46.25 |
| AVG Volume (30 Days) | 667.2K | ★ 994.2K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.46 | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $460,156,000.00 | $376,572,000.00 |
| Revenue This Year | $14.46 | $18.91 |
| Revenue Next Year | $29.47 | $15.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.33 | ★ 20.32 |
| 52 Week Low | $15.96 | $23.30 |
| 52 Week High | $44.34 | $57.88 |
Technical Indicators
Market Signals| Indicator | ZLAB | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 60.55 | 55.21 |
| Support Level | $19.51 | $41.85 |
| Resistance Level | $27.23 | $57.88 |
| Average True Range (ATR) | 0.67 | 2.90 |
| MACD | 0.27 | 0.55 |
| Stochastic Oscillator | 84.06 | 75.74 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.